UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2024
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | Commission File Number | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: (650 ) 243-6300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. | ||
Emerging growth company | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||
Item 2.02. Results of Operations and Financial Condition.
On February 22, 2024, Veracyte, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: | February 22, 2024 | ||||||||||
VERACYTE, INC. | |||||||||||
By: | /s/ Rebecca Chambers | ||||||||||
Name: | Rebecca Chambers | ||||||||||
Title: | Chief Financial Officer | ||||||||||
| Principal Financial Officer | |||||||||||
Exhibit 99.1
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
Grew Fourth Quarter Revenue to $98.2 million
Increased 2023 Total Revenue 22% to $361.1 million
Conference Call and Webcast Today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., February 22, 2024 --- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.
“We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher businesses,” said Marc Stapley, Veracyte’s chief executive officer. “Looking to 2024 and beyond, we will leverage our Veracyte Diagnostics Platform to continue to drive near- and long-term revenue. With multiple growth catalysts over the coming years and with our strong financial discipline, we expect to achieve positive cash flow for the third consecutive year and going forward.”
Key Business Highlights
•Grew total test volume to 33,836 in the fourth quarter and 126,977 for the full year 2023, an increase of 21% and 24%, respectively, compared to the prior year periods.
•Enhanced our Endocrinology offering in 2023 with the launch of TERT promoter mutation testing for Afirma, the introduction of our Afirma GRID research tool, and enhancements to our online physician ordering portal.
•Continued to strengthen the body of evidence for Decipher Prostate in 2023, adding 8 publications and 16 abstracts to the clinical-evidence library, reinforcing Decipher's status as the only molecular test to receive Level 1 evidence designation in the National Comprehensive Cancer Network’s (NCCN) prostate cancer guidelines.
•Acquired C2i Genomics Inc., adding whole-genome minimal residual disease (MRD) capabilities to our novel Veracyte Diagnostics Platform and expanding our ability to serve patients across the cancer care continuum.
•Signed an agreement with Illumina to develop some of our tests as in vitro diagnostics (IVDs) for use on their NextSeq 550Dx next-generation sequencing (NGS) instrument, as part of our multi-platform strategy to accelerate global expansion of our tests as IVDs.
•Published the clinical validation study for our Percepta Nasal Swab test in CHEST.
•For the full year, generated $44 million of cash from operations and ended the year with $216 million of cash and cash equivalents.
Fourth Quarter 2023 Financial Results
Total revenue for the fourth quarter of 2023 was $98.2 million, an increase of 22% compared to $80.3 million reported in the fourth quarter of 2022. Testing revenue was $90.4 million, an increase of 29% compared to $70.3 million in the fourth quarter of 2022, driven primarily by the strong performance of our Decipher Prostate and Afirma tests. Product revenue was $3.7 million, an increase of 13% compared to $3.2 million in the fourth quarter of 2022. Biopharmaceutical and other revenue was $4.1 million, a decrease of 39% compared to $6.8 million in the fourth quarter of 2022.
Total gross margin for the fourth quarter of 2023, including the amortization of acquired intangible assets, was 66%, compared to 61% in the fourth quarter of 2022. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 70%, compared to 67% in the fourth quarter of 2022.
Operating expenses, excluding cost of revenue, were $100.3 million, which included an impairment charge of $32.0 million associated with the impairment of HalioDx developed biopharmaceutical services technology,
customer relationships and customer backlog finite-lived intangible assets, compared to $54.1 million in the fourth quarter of 2022. Non-GAAP operating expenses, which excludes cost of revenue, amortization of acquired intangible assets, impairment charges, other acquisition related expenses and other restructuring costs, grew 28% to $65.6 million, including a technology access fee of $3.5 million to develop our IVD kitted tests on an NGS platform, compared to $51.1 million in the fourth quarter of 2022.
Net loss for the fourth quarter of 2023 was $28.3 million, and basic and diluted net loss per common share was $0.39, which includes the aforementioned $32.0 million impairment charge. Net cash provided by operating activities in the fourth quarter of 2023 was $15.6 million, an improvement of $5.8 million compared to the same period in 2022.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."
Full Year 2023 Financial Results
Total revenue for 2023 was $361.1 million, an increase of 22% compared to $296.5 million in 2022. Testing revenue was $326.5 million, an increase of 30% compared to $250.5 million in 2022 driven primarily by the strong performance of our Decipher and Afirma tests. Product revenue was $15.6 million, an increase of 23% compared to $12.6 million in 2022. Biopharmaceutical and other revenue was $18.9 million, a decrease of 43% compared to $33.4 million in 2022, driven by the reduction of customer projects given overall spending constraints across the industry.
Total gross margin for the full year 2023, including the amortization of acquired intangible assets, was 64%, compared to 59% in 2022. Non-GAAP gross margin, excluding the amortization of acquired intangible assets and other acquisition related expenses was 69%, compared to 66% in 2022.
Operating expenses, excluding cost of revenue, were $315.5 million, an increase of 46% compared to $216.8 million in 2022. Non-GAAP operating expenses, which excludes cost of revenue, amortization of acquired intangible assets, impairment charges, other acquisition related expenses and other restructuring costs, grew 20% to $240.7 million compared to $200.3 million in 2022.
Net loss for the full year 2023 was $74.4 million,and basic and diluted net loss per common share was $1.02,which includes impairment charges of $68.3 million in the year. Net cash provided by operating activities in 2023 was $44.2 million, an increase of $36.7 million compared to 2022.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Note Regarding Use of Non-GAAP Financial Measures."
2024 Financial Outlook
The company is maintaining full-year 2024 total revenue guidance of $394 million to $402 million and consistent with prior guidance, expects cash, cash equivalents and short-term investments at the end of the year to be $230 million to $234 million.
Conference Call and Webcast Details
Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company's financial results and provide a general business update. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/tkiac6t9. The webcast should be accessed 10 minutes prior to the conference call start time. A replay of the webcast will be available for one year following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
The conference call dial-in can be accessed by registering at the following link: https://register.vevent.com/register/BI38de228ea0a04e0ab786cfe56be5ca1b
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing
cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to 2024 financial and operating results; statements regarding the expected benefits of the acquisition of C2i Genomics; and our intentions with respect to our tests and products, for use in diagnosing and treating diseases, in and outside of the United States. Forward-looking statements can be identified by words such as: “appears,” “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” “enable,” “positioned,” “offers,” “designed” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: our ability to launch, commercialize and receive reimbursement for our products; our ability to execute on our business strategies relating to the C2i Genomics acquisition, integration the business and realize expected benefits and synergies; our ability to demonstrate the validity and utility of our genomic tests and biopharma and other offerings; our ability to continue executing on our business plan; our ability to continue to scale our global operations and enhance our internal control environment; the impact of the war in Ukraine and other regional conflicts on European economies and energy supply, as well as our facilities in France; the impact of foreign currency fluctuations, increasing interest rates, inflation, potential government shutdowns and turmoil in the global banking and finance system; and the performance and utility of our tests in the clinical environment. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed on March 1, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended September 30, 2023, filed on November 8, 2023, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.
Veracyte, the Veracyte logo, Decipher, C2i Genomics, and Afirma are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.
Note Regarding Use of Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release and the accompanying tables contain, and reference certain non‐GAAP results including non-GAAP gross margin, non-GAAP operating expenses, and non-GAAP loss from operations. These measures are not meant to be considered superior to or a substitute for financial measures calculated in accordance with GAAP, and investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures as an analytical tool.
We use non-GAAP measures to internally evaluate and analyze financial results. We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and enable comparison of our financial results with other public companies, many of which present similar non-GAAP financial measures. However, the non-GAAP measures we present may be different from those used by other companies.
We exclude amortization of acquired intangible assets, acquisition-related expenses relating to our acquisitions of Decipher Biosciences, HalioDx and C2i Genomics, impairment charges associated with the nCounter license and other biopharmaceutical services related HalioDx intangible assets and certain costs related to restructuring from certain of our non-GAAP measures. Management has excluded the effects of these items in non-GAAP measures to help investors gain a better understanding of the core operating results and future prospects of the company, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods or forecasts. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non‐GAAP information and the reconciliation between these presentations, to more fully understand its business.
Reconciliations between our GAAP results and non‐GAAP financial measures are presented in the tables of this release.
| VERACYTE, INC. | |||||||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||
| (In thousands, except share and per share amounts) | |||||||||||||||||||||||
| Three Months Ended December 31 | Twelve Months Ended December 31 | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Testing revenue | $ | 90,385 | $ | 70,269 | $ | 326,542 | $ | 250,544 | |||||||||||||||
| Product revenue | 3,665 | 3,231 | 15,588 | 12,632 | |||||||||||||||||||
| Biopharmaceutical and other revenue | 4,149 | 6,797 | 18,921 | 33,360 | |||||||||||||||||||
| Total revenue | 98,199 | 80,297 | 361,051 | 296,536 | |||||||||||||||||||
| Operating expenses (1): | |||||||||||||||||||||||
| Cost of testing revenue | 24,105 | 19,394 | 88,913 | 75,317 | |||||||||||||||||||
| Cost of product revenue | 1,753 | 2,618 | 8,666 | 7,820 | |||||||||||||||||||
| Cost of biopharmaceutical and other revenue | 3,518 | 4,819 | 15,324 | 18,445 | |||||||||||||||||||
| Research and development | 18,673 | 11,287 | 57,305 | 40,603 | |||||||||||||||||||
| Selling and marketing | 25,260 | 24,127 | 101,490 | 97,560 | |||||||||||||||||||
| General and administrative | 23,795 | 18,208 | 86,229 | 73,200 | |||||||||||||||||||
| Impairment of long-lived assets | 32,039 | — | 68,349 | 3,318 | |||||||||||||||||||
| Intangible asset amortization | 4,563 | 5,264 | 20,570 | 21,354 | |||||||||||||||||||
| Total operating expenses | 133,706 | 85,717 | 446,846 | 337,617 | |||||||||||||||||||
| Loss from operations | (35,507) | (5,420) | (85,795) | (41,081) | |||||||||||||||||||
| Other income, net | 5,035 | 1,979 | 9,183 | 4,654 | |||||||||||||||||||
| Loss before income taxes | (30,472) | (3,441) | (76,612) | (36,427) | |||||||||||||||||||
| Income tax (benefit) provision | (2,179) | 403 | (2,208) | 133 | |||||||||||||||||||
| Net loss | $ | (28,293) | $ | (3,844) | $ | (74,404) | $ | (36,560) | |||||||||||||||
| Net loss per common share, basic and diluted | $ | (0.39) | $ | (0.05) | $ | (1.02) | $ | (0.51) | |||||||||||||||
| Shares used to compute net loss per common share, basic and diluted | 73,107,059 | 71,825,754 | 72,644,487 | 71,549,204 | |||||||||||||||||||
1. Cost of revenue, research and development, sales and marketing and general and administrative expenses include the following stock-based compensation related expenses:
| Three Months Ended December 31 | Twelve Months Ended December 31 | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Cost of revenue | $ | 472 | $ | 408 | $ | 1,858 | $ | 1,355 | |||||||||||||||
| Research and development | 1,495 | 1,332 | 5,326 | 6,132 | |||||||||||||||||||
| Selling and marketing | 2,498 | 1,297 | 9,624 | 6,018 | |||||||||||||||||||
| General and administrative | 3,142 | 3,997 | 16,681 | 13,951 | |||||||||||||||||||
| Total stock-based compensation expense | $ | 7,607 | $ | 7,034 | $ | 33,489 | $ | 27,456 | |||||||||||||||
| VERACYTE, INC. | |||||||||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE LOSS | |||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||||
| Three Months Ended December 31 | Twelve Months Ended December 31 | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Net loss | $ | (28,293) | $ | (3,844) | $ | (74,404) | $ | (36,560) | |||||||||||||||
| Other comprehensive income (loss): | |||||||||||||||||||||||
| Change in currency translation adjustments | 3,765 | 22,720 | 7,328 | (16,263) | |||||||||||||||||||
| Net comprehensive loss | $ | (24,528) | $ | 18,876 | $ | (67,076) | $ | (52,823) | |||||||||||||||
| VERACYTE, INC. | |||||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
| (In thousands) | |||||||||||
| December 31 | December 31, | ||||||||||
| 2023 | 2022 | ||||||||||
| (Unaudited) | (See Note 1) | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 216,454 | $ | 154,247 | |||||||
| Short-term investments | — | 24,605 | |||||||||
| Accounts receivable | 40,378 | 44,021 | |||||||||
| Supplies and inventory | 16,128 | 14,294 | |||||||||
| Prepaid expenses and other current assets | 12,661 | 11,469 | |||||||||
Total current assets | 285,621 | 248,636 | |||||||||
| Property, plant and equipment, net | 20,584 | 17,702 | |||||||||
| Right-of-use assets, operating leases | 10,277 | 13,160 | |||||||||
| Intangible assets, net | 88,593 | 174,866 | |||||||||
| Goodwill | 702,984 | 695,891 | |||||||||
| Restricted cash | 876 | 749 | |||||||||
| Other assets | 5,971 | 5,418 | |||||||||
| Total assets | $ | 1,114,906 | $ | 1,156,422 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 12,943 | $ | 11,911 | |||||||
| Accrued liabilities | 38,427 | 37,774 | |||||||||
| Current portion of deferred revenue | 2,008 | 2,613 | |||||||||
| Current portion of acquisition-related contingent consideration | 2,657 | 6,060 | |||||||||
| Current portion of operating lease liabilities | 5,105 | 4,070 | |||||||||
| Current portion of other liabilities | 101 | 186 | |||||||||
Total current liabilities | 61,241 | 62,614 | |||||||||
| Deferred tax liabilities | 734 | 4,531 | |||||||||
| Acquisition-related contingent consideration, net of current portion | 518 | 2,498 | |||||||||
| Operating lease liabilities, net of current portion | 7,525 | 10,648 | |||||||||
| Other liabilities | 786 | 931 | |||||||||
Total liabilities | 70,804 | 81,222 | |||||||||
| Total stockholders’ equity | 1,044,102 | 1,075,200 | |||||||||
| Total liabilities and stockholders’ equity | $ | 1,114,906 | $ | 1,156,422 | |||||||
| 1. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited financial statements at that date included in the Company's Form 10-K filed with the Securities and Exchange Commission dated March 1, 2023. | |||||||||||
| VERACYTE, INC. | |||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||
| (Unaudited) | |||||||||||
| (In thousands) | |||||||||||
| Twelve Months Ended December 31 | |||||||||||
| 2023 | 2022 | ||||||||||
| Operating activities | |||||||||||
| Net loss | $ | (74,404) | $ | (36,560) | |||||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||
| Depreciation and amortization | 27,188 | 25,928 | |||||||||
| Loss on disposal of property and equipment | 271 | 206 | |||||||||
| Stock-based compensation | 33,141 | 26,734 | |||||||||
| Deferred income taxes | (3,839) | 133 | |||||||||
| Interest on end-of-term debt obligation | — | 161 | |||||||||
| Noncash lease expense | 4,158 | 3,320 | |||||||||
| Revaluation of acquisition-related contingent consideration | (5,383) | 154 | |||||||||
| Impairment loss | 68,349 | 3,318 | |||||||||
| Effect of foreign currency on operations | (1,096) | 522 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | 3,887 | (4,495) | |||||||||
| Supplies and inventory | (1,694) | (3,011) | |||||||||
| Prepaid expenses and other current assets | (458) | 1,390 | |||||||||
| Other assets | (758) | (3,049) | |||||||||
| Operating lease liability | (4,330) | (3,448) | |||||||||
| Accounts payable | (134) | 152 | |||||||||
| Accrued liabilities and deferred revenue | (676) | (3,920) | |||||||||
| Net cash provided by operating activities | 44,222 | 7,535 | |||||||||
| Investing activities | |||||||||||
| Purchase of short-term investments | (19,700) | (33,519) | |||||||||
| Proceeds from sale of short-term investments | 39,773 | — | |||||||||
| Proceeds from maturity of short-term investments | 5,000 | 12,681 | |||||||||
| Purchases of property, plant and equipment | (9,961) | (8,549) | |||||||||
| Net cash provided by (used in) investing activities | 15,112 | (29,387) | |||||||||
| Financing activities | |||||||||||
| Payment of long-term debt | — | (1,281) | |||||||||
| Payment of taxes on vested restricted stock units | (6,741) | (3,167) | |||||||||
| Proceeds from the exercise of common stock options and employee stock purchases | 9,578 | 7,942 | |||||||||
| Net cash provided by financing activities | 2,837 | 3,494 | |||||||||
| Increase (decrease) in cash, cash equivalents and restricted cash | 62,171 | (18,358) | |||||||||
| Effect of foreign currency on cash, cash equivalents and restricted cash | 163 | (592) | |||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 62,334 | (18,950) | |||||||||
| Cash, cash equivalents and restricted cash at beginning of year | 154,996 | 173,946 | |||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 217,330 | $ | 154,996 | |||||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH | |||||||||||
| (Unaudited) | |||||||||||
| (In thousands) | |||||||||||
| December 31 | December 31, | ||||||||||
| 2023 | 2022 | ||||||||||
| Cash and cash equivalents | $ | 216,454 | $ | 154,247 | |||||||
| Restricted cash | 876 | 749 | |||||||||
| Total cash, cash equivalents and restricted cash | $ | 217,330 | $ | 154,996 | |||||||
| Reconciliation of U.S. GAAP to Non-GAAP Financial Measures | |||||||||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||||||||||
| Identified Expenses | |||||||||||||||||||||||||||||
| GAAP | Acquisition Related Expenses (1) | Intangible Assets Amortization Expense | Other (4) | Total Non-GAAP Measure | |||||||||||||||||||||||||
| Three Months Ended December 31, 2023 | |||||||||||||||||||||||||||||
| Total revenue | $ | 98,199 | $ | — | $ | — | $ | — | $ | 98,199 | |||||||||||||||||||
| Cost of testing revenue | 24,105 | — | — | — | 24,105 | ||||||||||||||||||||||||
| Cost of product revenue | 1,753 | — | — | — | 1,753 | ||||||||||||||||||||||||
| Cost of biopharmaceutical and other revenue | 3,518 | — | — | — | 3,518 | ||||||||||||||||||||||||
| Intangible asset amortization (2) | 4,035 | — | 4,035 | — | — | ||||||||||||||||||||||||
| Gross margin $ | 64,788 | — | 4,035 | — | 68,823 | ||||||||||||||||||||||||
| Gross margin % | 66 | % | 70 | % | |||||||||||||||||||||||||
| Research and development | 18,673 | — | — | — | 18,673 | ||||||||||||||||||||||||
| Selling and marketing | 25,260 | 294 | — | — | 24,966 | ||||||||||||||||||||||||
| General and administrative | 23,795 | 1,867 | — | — | 21,928 | ||||||||||||||||||||||||
| Impairment of long-lived assets | 32,039 | — | — | 32,039 | — | ||||||||||||||||||||||||
| Intangible asset amortization | 528 | — | 528 | — | — | ||||||||||||||||||||||||
| Total operating expenses excluding cost of revenue (3) | 100,295 | 2,161 | 528 | 32,039 | 65,567 | ||||||||||||||||||||||||
| Income (loss) from operations | $ | (35,507) | $ | 2,161 | $ | 4,563 | $ | 32,039 | $ | 3,256 | |||||||||||||||||||
| Three Months Ended December 31, 2022 | |||||||||||||||||||||||||||||
| Total revenue | $ | 80,297 | $ | — | $ | — | $ | — | $ | 80,297 | |||||||||||||||||||
| Cost of testing revenue | 19,394 | 50 | — | — | 19,344 | ||||||||||||||||||||||||
| Cost of product revenue | 2,618 | — | — | — | 2,618 | ||||||||||||||||||||||||
| Cost of biopharmaceutical and other revenue | 4,819 | 64 | — | — | 4,755 | ||||||||||||||||||||||||
| Intangible asset amortization (2) | 4,747 | — | 4,747 | — | — | ||||||||||||||||||||||||
| Gross margin $ | 48,719 | 114 | 4,747 | — | 53,580 | ||||||||||||||||||||||||
| Gross margin % | 61 | % | 67 | % | |||||||||||||||||||||||||
| Research and development | 11,287 | 232 | — | — | 11,055 | ||||||||||||||||||||||||
| Selling and marketing | 24,127 | 917 | — | — | 23,210 | ||||||||||||||||||||||||
| General and administrative | 18,208 | 1,368 | — | — | 16,840 | ||||||||||||||||||||||||
| Impairment of long-lived assets | — | — | — | — | — | ||||||||||||||||||||||||
| Intangible asset amortization | 517 | — | 517 | — | — | ||||||||||||||||||||||||
| Total operating expenses excluding cost of revenue (3) | 54,139 | 2,517 | 517 | — | 51,105 | ||||||||||||||||||||||||
| Income (loss) from operations | $ | (5,420) | $ | 2,631 | $ | 5,264 | $ | — | $ | 2,475 | |||||||||||||||||||
| 1. Includes transaction related expenses as well as post-combination compensation expenses. For each of the three months ended December 31, 2022, and December 31, 2023, adjustments consist primarily of remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy and post-combination compensation expenses associated with the acquisition of HalioDx. For the three months ended December 31, 2023 adjustments include the transaction related expenses associated with the acquisition of C2i Genomics. | |||||||||||||||||||||||||||||
| 2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue. | |||||||||||||||||||||||||||||
| 3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue ($29.4 million and $26.8 million) and the amortization of intangible assets which would have been allocated to the cost of revenue ($4.0 million and $4.7 million) for the three months ended December 31, 2023 and for the three months ended December 31, 2022 respectively. | |||||||||||||||||||||||||||||
| 4. For the three months ended December 31, 2023, includes $32.0 million expense related to the impairment charge associated with HalioDx developed technology, customer relationships and customer backlog finite-lived intangible assets. | |||||||||||||||||||||||||||||
| Reconciliation of U.S. GAAP to Non-GAAP Financial Measures | |||||||||||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||||||||||
| Identified Expenses | |||||||||||||||||||||||||||||
| GAAP | Acquisition Related Expenses (1) | Intangible Assets Amortization Expense | Other (4) | Total Non-GAAP Measure | |||||||||||||||||||||||||
| Twelve Months Ended December 31, 2023 | |||||||||||||||||||||||||||||
| Total revenue | $ | 361,051 | $ | — | $ | — | $ | — | $ | 361,051 | |||||||||||||||||||
| Cost of testing revenue | 88,913 | 83 | — | — | 88,830 | ||||||||||||||||||||||||
| Cost of product revenue | 8,666 | — | — | — | 8,666 | ||||||||||||||||||||||||
| Cost of biopharmaceutical and other revenue | 15,324 | 94 | — | — | 15,230 | ||||||||||||||||||||||||
| Intangible asset amortization (2) | 18,464 | — | 18,464 | — | — | ||||||||||||||||||||||||
| Gross margin $ | 229,684 | 177 | 18,464 | — | 248,325 | ||||||||||||||||||||||||
| Gross margin % | 64 | % | 69 | % | |||||||||||||||||||||||||
| Research and development | 57,305 | 58 | — | — | 57,247 | ||||||||||||||||||||||||
| Selling and marketing | 101,490 | 2,610 | — | — | 98,880 | ||||||||||||||||||||||||
| General and administrative | 86,229 | 329 | — | 1,371 | 84,529 | ||||||||||||||||||||||||
| Impairment of long-lived assets | 68,349 | — | — | 68,349 | — | ||||||||||||||||||||||||
| Intangible asset amortization | 2,106 | — | 2,106 | — | — | ||||||||||||||||||||||||
| Total operating expenses excluding cost of revenue (3) | 315,479 | 2,997 | 2,106 | 69,720 | 240,656 | ||||||||||||||||||||||||
| Income (loss) from operations | $ | (85,795) | $ | 3,174 | $ | 20,570 | $ | 69,720 | $ | 7,669 | |||||||||||||||||||
| Twelve Months Ended December 31, 2022 | |||||||||||||||||||||||||||||
| Total revenue | $ | 296,536 | $ | — | $ | — | $ | — | $ | 296,536 | |||||||||||||||||||
| Cost of testing revenue | 75,317 | 203 | — | 18 | 75,096 | ||||||||||||||||||||||||
| Cost of product revenue | 7,820 | — | — | 3 | 7,817 | ||||||||||||||||||||||||
| Cost of biopharmaceutical and other revenue | 18,445 | 325 | — | — | 18,120 | ||||||||||||||||||||||||
| Intangible asset amortization (2) | 19,273 | — | 19,273 | — | — | ||||||||||||||||||||||||
| Gross margin $ | 175,681 | 528 | 19,273 | 21 | 195,503 | ||||||||||||||||||||||||
| Gross margin % | 59 | % | 66 | % | |||||||||||||||||||||||||
| Research and development | 40,603 | 1,418 | — | — | 39,185 | ||||||||||||||||||||||||
| Selling and marketing | 97,560 | 3,914 | — | 493 | 93,153 | ||||||||||||||||||||||||
| General and administrative | 73,200 | 5,245 | — | — | 67,955 | ||||||||||||||||||||||||
| Impairment of long-lived assets | 3,318 | — | — | 3,318 | — | ||||||||||||||||||||||||
| Intangible asset amortization | 2,081 | — | 2,081 | — | — | ||||||||||||||||||||||||
| Total operating expenses excluding cost of revenue (3) | 216,762 | 10,577 | 2,081 | 3,811 | 200,293 | ||||||||||||||||||||||||
| Loss from operations | $ | (41,081) | $ | 11,105 | $ | 21,354 | $ | 3,832 | $ | (4,790) | |||||||||||||||||||
| 1. Includes transaction related expenses as well as post-combination compensation expenses, adjustments consist primarily remeasurement of contingent consideration related to our adoption of a multi-platform IVD strategy, post-combination compensation expenses associated with the acquisition of HalioDx and transaction related expenses associated with the acquisition of C2i Genomics. | |||||||||||||||||||||||||||||
| 2. Includes only amortization of intangible assets identified as developed technology assets through purchase accounting transactions, which otherwise would have been allocated to cost of revenue. | |||||||||||||||||||||||||||||
| 3. Includes only amortization of intangible assets, which otherwise would have been allocated to research and development, selling and marketing or general and administrative expense and excludes the cost of revenue ($112.9 and $101.6 million) and the amortization of intangible assets which would have been allocated to the cost of revenue ($18.5 and $19.3 million) for the full year 2023 and 2022 respectively. | |||||||||||||||||||||||||||||
| 4. 2022 includes $3.3 million expense related to the impairment charge associated with certain developed technology intangible assets; 2023 includes $34.9 million expense related to the impairment charge associated with the nCounter license intangible assets, $32.0 million related to the impairment charge associated with HalioDx developed technology, customer relationships and customer backlog finite-lived intangible assets, $1.4 million related to the departure of the former executive chair and $1.4 million related to restructuring costs. | |||||||||||||||||||||||||||||
# # #
Investor Contact:
Shayla Gorman
investors@veracyte.com
619-393-1545
Media Contact:
Tracy Morris
media@veracyte.com
650-380-4413